What changed today in Metabolic: 20 trial updates, 9 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records13 sources1 min read
Diabetes developments
Developments in type 2 diabetes care relevant to pharmacy and metabolic practice, including incretin therapies and cardiometabolic outcomes.
High attention
- Editorial attention
- High attention
- Tracked this week
- 15
- Sources this week
- 7
- Last activity
- 10 hrs ago
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Diabetes developments at a glance
- About this topic
- Developments in type 2 diabetes care relevant to pharmacy and metabolic practice, including incretin therapies and cardiometabolic outcomes.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: Results posted on ClinicalTrials.gov: ACHIEVE-5 (A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin…) (opens the source in a new tab) (ClinicalTrials.gov (U.S. National Library of Medicine), Sep 30, 2026)
- Key facts from tracked records
- 1 NPHLA briefing on this topic
What’s the latest on Diabetes developments?
1 totalWhat do the official records show?
Primary sources and peer-reviewed research- Results posted on ClinicalTrials.gov: ACHIEVE-5 (A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin…) (opens the source in a new tab)
Phase 3, Eli Lilly and Company. Conditions: Type 2 Diabetes. Interventions: Orforglipron; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
- Lipoedema and Obesity Misclassification: A Phenotype Based Approach to Cardiometabolic Risk Beyond Body Mass Index (opens the source in a new tab)
- New trial registered: Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema (opens the source in a new tab)
Phase 3, Novo Nordisk A/S. Conditions: Diabetes Mellitus, Type 2. Interventions: CagriSema. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: TELWA (Probiotics in Obese Patients Treated With GLP-1 Receptor Agonists) (opens the source in a new tab)
Not applicable, Nordic Biotic Sp. z o.o.. Conditions: Obesity (Disorder); GLP-1 Receptor Agonist Treatment; Probiotic Intervention; Diabetes Mellitus Type 2. Interventions: Four-strain probiotic formulation; Maltodextrin (Placebo). Investigational: trial-stage therapies are no…
- New trial registered: Body Composition Changes After Initiation of GLP-1 Receptor Agonists in Adults With Obesity or Type 2 Diabetes (opens the source in a new tab)
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran. Conditions: Obesity (Disorder); Type 2 Diabetes Mellitus. Interventions: . Investigational: trial-stage therapies are not approved for the use studied.
- Results posted on ClinicalTrials.gov: ACHIEVE-3 (A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately…) (opens the source in a new tab)
Phase 3, Eli Lilly and Company. Conditions: Type 2 Diabetes. Interventions: Orforglipron; Semaglutide. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: TrichoscopyDM2 (Hair Changes in Females With Type 2 Diabetes Clinical and Trichoscopic Examination) (opens the source in a new tab)
Al-Azhar University. Conditions: Diabete Mellitus; Female Androgenetic Alopecia; Dermoscopy. Interventions: . Investigational: trial-stage therapies are not approved for the use studied.
- Results posted on ClinicalTrials.gov: ATTAIN-2 (A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes) (opens the source in a new tab)
Phase 3, Eli Lilly and Company. Conditions: Obesity; Overweight; Type 2 Diabetes. Interventions: Orforglipron; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
Industry coverage
Headlines link to the original publication- New Easier-to-Use GLP-1 Pill Safe for the Heart, Study Says (opens the source in a new tab)
- #EASD26: Lilly's triple-G allows 60% of patients to drop below obesity threshold (opens the source in a new tab)
- #EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes (opens the source in a new tab)
- Orforglipron Edges Oral Semaglutide 25 mg in T2D, Indirect Comparison Finds (opens the source in a new tab)
- Retatrutide Cuts Weight Up to 18.8% in Adults With T2D, Obesity (opens the source in a new tab)
- #EASD26: Boehringer's weight loss candidate trails rivals in diabetes and obesity (opens the source in a new tab)